Is Acrivon Therapeutics, Inc. (ACRV) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.5% / 30% | 367.0% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 7.5% / 33% | 367.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.9% / 33% | 91.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 7.5% / 33% | 367.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.9% / 33% | 91.3% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.9% | |
| Return on Assets (ROA) | -32.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$66M |
| Free Cash Flow | -$68M |
| Total Debt | $4M |
| Debt-to-Equity | 2.4 |
| Current Ratio | 7.7 |
| Total Assets | $197M |
Price & Trading
| Last Close | $1.42 |
| 50-Day MA | $1.68 |
| 200-Day MA | $1.74 |
| Avg Volume | 1.8M |
| Beta | 1.8 |
|
52-Week Range
$1.05
| |
About Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Acrivon Therapeutics, Inc. (ACRV) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Acrivon Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Acrivon Therapeutics, Inc.'s debt ratio?
Acrivon Therapeutics, Inc.'s debt ratio is 7.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.9%.
What are Acrivon Therapeutics, Inc.'s key financial metrics?
Acrivon Therapeutics, Inc. has a market capitalization of $52M. Return on equity stands at -53.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.